Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Latiglutenase (ALV003 / BL-7010) (Investigational)
Treatment for Celiac Disease
Typical Dosage: 300 mg before meals
Effectiveness
55%
Safety Score
80%
Clinical Trials
8
Participants
1.5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
80
DangerousModerateSafe
Treatment Details
Dosage Range
300 mg before meals
Time to Effect
With meals
Treatment Duration
Long-term, with meals
Evidence Quality
MODERATENumber Needed to Treat (NNT)
9(Treat 9 patients to see 1 additional successful outcome)
Confidence Score
60%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$4,500
Monitoring:$100
Side Effect Mgmt:$50
Total Annual:$4,650
Cost-Effectiveness Analysis
QALYs Gained
0.15
Outcome-Based Costs
Cost per Responder
$13,285
Prescription Access Economics
Latiglutenase (ALV003 / BL-7010) (Investigational) Outcomes
for Celiac Disease
Efficacy Outcomes
Overall Effectiveness
+55%
Response Rate
+35%
Common Side Effects
Abdominal pain
+12%
Flatulence
+10%
Nausea
+5%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov